Latest Orencia Stories
Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year, 64.8% of patients receiving abatacept (Orencia) and 63.4% of patients receiving adalimumab (Humira) achieved ACR20.
CAMBRIDGE, Mass., April 1 /PRNewswire/ -- Sermo (http://www.sermo.com), the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs - Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB).
EXTON, Pa., Dec. 14 /PRNewswire/ -- BioTrends Research Group, Inc. released ChartTrendsÂ®: Biologics in Rheumatoid Arthritis, a syndicated publication offering comprehensive insight into the management of RA patients.
WALTHAM, Mass., July 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed rheumatologists' perception of Bristol-Myers Squibb's Orencia is low among rheumatoid arthritis agents.
Recent Entrants Invest Heavily in Promotion to Capture Share in Mature Market, According to a New Report from Decision Resources WALTHAM, Mass., Jan.
Bristol-Myers Squibb Company (NYSE: BMY) today announced at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results from a 10-month study which showed that ORENCIA(R) (abatacept), compared to placebo, significantly improved multiple aspects of health-related quality of life (HRQoL): physical and psychosocial well being, pain and sleep quality in juvenile idiopathic arthritis (JIA) patients between the ages 6 and 17 years.
Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase IIIb study in adult patients with early moderate-to-severe erosive rheumatoid arthritis (RA) who had never received previous methotrexate (MTX) treatment.
- Emitting flashes of light; glittering.